408 related articles for article (PubMed ID: 31013372)
1. Parent and child perception of quality of life in a randomized controlled peanut oral immunotherapy trial.
Reier-Nilsen T; Carlsen KCL; Michelsen MM; Drottning S; Carlsen KH; Zhang C; Borres MP; Håland G
Pediatr Allergy Immunol; 2019 Sep; 30(6):638-645. PubMed ID: 31013372
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Quality of Life in a Multicenter, Randomized, Placebo-Controlled Trial of Low-Dose Peanut Oral Immunotherapy in Children with Peanut Allergy.
Blumchen K; Trendelenburg V; Ahrens F; Gruebl A; Hamelmann E; Hansen G; Heinzmann A; Nemat K; Holzhauser T; Roeder M; Rosenfeld L; Hartmann O; Niggemann B; Beyer K
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):479-491.e10. PubMed ID: 30423449
[TBL] [Abstract][Full Text] [Related]
3. Allergen-specific oral immunotherapy for peanut allergy.
Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
Cochrane Database Syst Rev; 2012 Sep; (9):CD009014. PubMed ID: 22972130
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of desensitizing children highly allergic to peanut by high-dose oral immunotherapy.
Reier-Nilsen T; Michelsen MM; Lødrup Carlsen KC; Carlsen KH; Mowinckel P; Nygaard UC; Namork E; Borres MP; Håland G
Allergy; 2019 Feb; 74(2):337-348. PubMed ID: 30225844
[TBL] [Abstract][Full Text] [Related]
5. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
[TBL] [Abstract][Full Text] [Related]
6. Peanut oral immunotherapy in a pediatric allergy clinic: Patient factors associated with clinical outcomes.
Guarnieri KM; Slack IF; Gadoury-Lévesque V; Eapen AA; Andorf S; Lierl MB
Ann Allergy Asthma Immunol; 2021 Aug; 127(2):214-222.e4. PubMed ID: 33839246
[TBL] [Abstract][Full Text] [Related]
7. Peanut Oral Immunotherapy With or Without H
Chu DK; Freitag T; Marrin A; Walker TD; Avilla E; Freitag A; Spill P; Foster GA; Thabane L; Jordana M; Waserman S
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2386-2394. PubMed ID: 35643280
[TBL] [Abstract][Full Text] [Related]
8. Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan.
Nagakura KI; Yanagida N; Sato S; Nishino M; Asaumi T; Ogura K; Ebisawa M
Pediatr Allergy Immunol; 2018 Aug; 29(5):512-518. PubMed ID: 29603410
[TBL] [Abstract][Full Text] [Related]
9. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.
Vickery BP; Berglund JP; Burk CM; Fine JP; Kim EH; Kim JI; Keet CA; Kulis M; Orgel KG; Guo R; Steele PH; Virkud YV; Ye P; Wright BL; Wood RA; Burks AW
J Allergy Clin Immunol; 2017 Jan; 139(1):173-181.e8. PubMed ID: 27522159
[TBL] [Abstract][Full Text] [Related]
10. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
Vickery BP; Scurlock AM; Kulis M; Steele PH; Kamilaris J; Berglund JP; Burk C; Hiegel A; Carlisle S; Christie L; Perry TT; Pesek RD; Sheikh S; Virkud Y; Smith PB; Shamji MH; Durham SR; Jones SM; Burks AW
J Allergy Clin Immunol; 2014 Feb; 133(2):468-75. PubMed ID: 24361082
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response.
Varshney P; Jones SM; Scurlock AM; Perry TT; Kemper A; Steele P; Hiegel A; Kamilaris J; Carlisle S; Yue X; Kulis M; Pons L; Vickery B; Burks AW
J Allergy Clin Immunol; 2011 Mar; 127(3):654-60. PubMed ID: 21377034
[TBL] [Abstract][Full Text] [Related]
12. High Degree of Desensitization After 1 Year of Early-Life Peanut Oral Immunotherapy: Small Children Oral Immunotherapy (SmaChO) Randomized Controlled Trial.
Uhl C; Klevebro S; Sverremark-Ekström E; Tedner SG; Brandström J; Papageorgiou C; Melén E; Konradsen JR; Nilsson C; Asarnoj A
J Allergy Clin Immunol Pract; 2024 May; 12(5):1297-1305. PubMed ID: 38428524
[TBL] [Abstract][Full Text] [Related]
13. Quality of life of children aged 8-12 years undergoing food allergy oral immunotherapy: Child and parent perspective.
Epstein-Rigbi N; Goldberg MR; Levy MB; Nachshon L; Elizur A
Allergy; 2020 Oct; 75(10):2623-2632. PubMed ID: 32350869
[TBL] [Abstract][Full Text] [Related]
14. Peanut Oral Immunotherapy: State of the Art.
Tang MLK; Lozinsky AC; Loke P
Immunol Allergy Clin North Am; 2020 Feb; 40(1):97-110. PubMed ID: 31761124
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
[TBL] [Abstract][Full Text] [Related]
16. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.
Patil SU; Steinbrecher J; Calatroni A; Smith N; Ma A; Ruiter B; Virkud Y; Schneider M; Shreffler WG
J Allergy Clin Immunol; 2019 Nov; 144(5):1310-1319.e4. PubMed ID: 31377342
[TBL] [Abstract][Full Text] [Related]
17. Oral Immunotherapy in Japanese Children with Anaphylactic Peanut Allergy.
Nagakura KI; Sato S; Yanagida N; Nishino M; Asaumi T; Ogura K; Ebisawa M
Int Arch Allergy Immunol; 2018; 175(3):181-188. PubMed ID: 29339650
[TBL] [Abstract][Full Text] [Related]
18. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
[TBL] [Abstract][Full Text] [Related]
19. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.
Anagnostou K; Islam S; King Y; Foley L; Pasea L; Bond S; Palmer C; Deighton J; Ewan P; Clark A
Lancet; 2014 Apr; 383(9925):1297-1304. PubMed ID: 24485709
[TBL] [Abstract][Full Text] [Related]
20. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial: a critical appraisal.
Marrs T; Flohr C; Perkin MR
Br J Dermatol; 2015 Nov; 173(5):1125-9. PubMed ID: 26769642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
